Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New chip could pick healthier sperm for IVF

NCT ID NCT03085433

Disease control Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a microfluidic chip that gently separates healthy, motile sperm from semen without harsh chemicals. Researchers compared it to the standard spinning method in 393 couples undergoing IVF for unexplained infertility. The goal was to see if the chip leads to higher-quality embryos on day 3 of development.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Microfluidic sperm sorting device
What this could lead to
If successful, this device could become a standard, gentler way to select sperm for IVF, potentially improving embryo quality and pregnancy chances.
What could go wrong
This is a completed trial, but the improvement in embryo quality may not translate into higher live birth rates. The device may not work for all types of male infertility.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

393 people

The number who actually took part.

Started

Jun 2017

Finished

Apr 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The target population includes couples planning in vitro fertilization (IVF) with intracytoplasmic sperm injection (ICSI). * Subjects with and without a history of prior IVF cycles will be included. * All eligible couples where both partners are \>=18 years of age will be asked to join the study. Exclusion Criteria: * Male partner with severe oligoasthenospermia (concentration \< 5 x 10\^6 spermatozoa/mL; motility\< 10%) * Female partner with anovulation (PCOS, FHA) * Female partner age \>41 * Female partner AFC\< 7 * Female partner with obstructed fallopian tubes (assessed in all patients prior to IVF) * Use of oocyte donor * Either Partner: * Cancer diagnosis in either partner * Any significant disease or psychiatric disorder that would interfere with consenting process * Treatment History: o History of \>1 prior cycle cancellation due to poor response * Treatment Plan: * Embryo co-culture * Use of adjunctive non-gonadotropin medications to improve embryo quality: growth hormone, sildenafil

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Embryo quality are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infertility disorder male infertility

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Embryo quality Fertility disorders Infertility Infertility unexplained Infertility, male Sperm DNA fragmentation

Contacts and locations

Locations

  • University of California San Francisco

    San Francisco, California, 94158, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.